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 ARTICLE IDENTIFICATION…………………………………...3 
 
Date of publication (year) 3 
 Title 3 
 First author 3 
 Journal 3 
 
 
 I. CONTEXT OF THE ANALYSIS………………………………...4 
 
 Team performing the analysis 4 




 II. CLINICAL STUDY(ies)…………………………………….........5 
  
 Phase(s) of clinical development 5 
 Main objective(s) of the clinical study(ies) 5 
 Target population of the clinical study(ies) 5 
 Administration route(s) 5 
 Dose 6 
 Number of center(s) involved 6 
 Duration of the clinical study(ies) 6
 Duration of the treatment(s) 6 
 Experimental design 6 
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 Antimicrobial Agents and Chemotherapy 
 British Journal of Clinical Pharmacology 
 Cancer Chemotherapy and Pharmacology 
 Clinical Pharmacokinetics 
 Clinical Pharmacology and Therapeutics 
 Clinical Therapeutics 
 European Journal of Cancer 
 European Journal of Clinical Pharmacology 
 European Journal of Drug Metabolism and Pharmacokinetics 
 European Journal of Pharmaceutical sciences 
 Journal of Acquired Immune Deficiency Syndromes 
 Journal of Clinical Oncology 
 Journal of Pharmaceutical Sciences 
 Journal of Pharmacokinetics and Pharmacodynamics 
 Journal of Pharmacy and Pharmacology 
 Therapeutic Drug Monitoring 
 Pharmacotherapy 
 Other:                         …………………………………………………….. 
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I. CONTEXT OF THE ANALYSIS 
 
Team performing the analysis 
 Industry (R & D)     Not reported 
 Academic/Hospital  
 Drug Agency 







Therapeutic class(es) studied in this analysis 2    Not reported 
 
 Antidotes  Antimicrobials 
 Antiparasitics  Cardiovascular-renal 
 Central nervous system  Contrast media / Radiopharmaceuticals 
 Gastrointestinals  Hematologics 
 Hormones / Hormonal mechanisms  Immunologics 
 Metabolics / Nutrients  Neurologics 
 Oncolytics  Ophtalmics 
 Otics   Pain relief 
 Respiratory tract   Skin / Mucous membranes 
 Other ……………………………………………………..  
                                                 
1 International Nonproprietary Names (=DCI) (if not published, company identification number)  
 
2 Major classes of  FDA National Drug Code Directory (http://www.fda.gov/cder/ndc/tbldclas.txt) 
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II. CLINICAL STUDY(ies) 
 
Phase(s) of clinical development  
 Combined studies  Not reported 
 Phase I  Phase III 
 Phase II  Observational studies 
 
Main objective(s) of the clinical study(ies)  
 PK  PD    Not reported 
 Dose finding   Drug interaction  
 Efficacy  TDM  
 Toxicity   Other:     ………………………………………………..  
 
Target population of the clinical study(ies) 
 Total number of Subjects:  ………………. 
 
 Adults          Paediatrics         Elderly    Not reported 
 Healthy volunteers   Patients   Special population  Not reported 
 
Administration route(s) 
 PO  Nasal    Not reported 
 IV (bolus)  IV (Infusion)  SC   Intraperitoneal 
 IM  Transdermal   Rectal   Ophtalmic  
 Other:  ……………………………………………………………..    
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 Single dose  Multiple doses  Not reported 
 Multiple cycles 
 
Number of center(s) involved 
 Monocentric    Not reported 
 Multicentric    
 
Duration of the clinical study(ies) 
……………… days  Unclear    Not reported 
 
Duration of the treatment(s) 
……………… days  Unclear    Not reported 
 
Experimental design 
Number of Arms:  …………………      Not reported 
 Cohort study  
 
if number of arms >1: 
  Parallel group        Not reported 
  Cross-over study 
 Dose escalation (titration) Yes No   Not reported 
    
 Randomization Yes No   Not reported 
    
 Is there a comparator?  
   None        Not reported 
   Placebo 
   Reference treatment(s)  
   Other, define:…………………………………   
Are the design optimised with respect to the sampling times 
  Yes No   
    
